UPCOMING EVENTS
Bio-Europe 2021
Digital
Bio-Europe 2021
From to
Through the pandemic and the pivot to digital, the “must-attend” BIO-Europe event series held true to its value proposition, using EBD’s proven digital event model. Fulfilling its mission for the sector to connect the international life science community, BIO-Europe will once more allow you to connect and interact, remotely and safely, over four days, October 25-28, 2021.
Chemtogether 2021
ETH Hönggerberg, Switzerland
G-Floor
Chemtogether 2021
From to
Chemtogether is an annual career fair at ETH Zurich for companies in the chemical and pharmaceutical industries. This year´s Chemtogether will take place on the 2nd and 3rd November 2021 on the G-floor of the HCI building on the ETH Hönggerberg campus. CARBOGEN AMCIS will participate on Wednesday, 3th of November 2021. Register yourself and join us!
CPhI Worldwide 2021
Fiera Milano
5D11
CPhI Worldwide 2021
From to
CPhI Worldwide will return to Milan from 09th November to 11th November 2021.
Over the last 30+ years, CPhI has provided a unique platform that unites specialist communities dedicated to improving healthcare. We offer a place where professionals can meet to exchange knowledge and do business without obstacles, helping to propel the pharmaceutical and healthcare industries forward.
A3P International Congress
3 Place Bellevue, 64200 Biarritz, France
O38
A3P International Congress
From to
Each year, nearly 650 professionals from the pharmaceutical and biotech industries meet in Biarritz to share their experiences and discover the technical and scientific innovations of the moment.
BioFIT 2021
Digital
BioFIT 2021
From to
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
LATEST NEWS
CARBOGEN AMCIS announces a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client
BUBENDORF, Switzerland (27 Aug 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co-investment agreement with one of its key European customers.
CARBOGEN AMCIS acquires new property at Bubendorf site
BUBENDORF, Switzerland (24 June, 2021) Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced the acquisition of a new property in Bubendorf.
CARBOGEN AMCIS announces a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site
BUBENDORF, Switzerland (April 29th, 2021) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long standing Japan based customer to build a site extension at the Bubendorf site in Switzerland.
Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency (2)
Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN AMCIS B.V.
CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France
We at Dishman Carbogen Amcis group of companies are taking the risks associated with COVID-19 very seriously, and have already implemented a set of measures aimed at limiting any risk to our employees, customers and patients. We have already established a dedicated working team who monitor the COVID-19 outbreak and all processes have been analyzed with regards to risks. This allows us to have all our operations running smoothly and we currently do not have an impact on our operations.
COVID-19
We at Dishman Carbogen Amcis group of companies are taking the risks associated with COVID-19 very seriously, and have already implemented a set of measures aimed at limiting any risk to our employees, customers and patients. We have already established a dedicated working team who monitor the COVID-19 outbreak and all processes have been analyzed with regards to risks. This allows us to have all our operations running smoothly and we currently do not have an impact on our operations.
For more information
download our Company Profile
brochure or contact us today.
